Literature DB >> 23998903

Crystallographic fragment-based drug discovery: use of a brominated fragment library targeting HIV protease.

Theresa Tiefenbrunn1, Stefano Forli, Meaghan Happer, Ana Gonzalez, Yingssu Tsai, Michael Soltis, John H Elder, Arthur J Olson, Charles D Stout.   

Abstract

A library of 68 brominated fragments was screened against a new crystal form of inhibited HIV-1 protease in order to probe surface sites in soaking experiments. Often, fragments are weak binders with partial occupancy, resulting in weak, difficult-to-fit electron density. The use of a brominated fragment library addresses this challenge, as bromine can be located unequivocally via anomalous scattering. Data collection was carried out in an automated fashion using AutoDrug at SSRL. Novel hits were identified in the known surface sites: 3-bromo-2,6-dimethoxybenzoic acid (Br6) in the flap site and 1-bromo-2-naphthoic acid (Br27) in the exosite, expanding the chemistry of known fragments for development of higher affinity potential allosteric inhibitors. At the same time, mapping the binding sites of a number of weaker binding Br-fragments provides further insight into the nature of these surface pockets.
© 2013 John Wiley & Sons A/S.

Entities:  

Keywords:  HIV protease; X-ray crystallography; fragment binding; structure-based drug design

Mesh:

Substances:

Year:  2013        PMID: 23998903      PMCID: PMC3898673          DOI: 10.1111/cbdd.12227

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  14 in total

1.  Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines.

Authors:  Timothy M McPhillips; Scott E McPhillips; Hsiu-Ju Chiu; Aina E Cohen; Ashley M Deacon; Paul J Ellis; Elspeth Garman; Ana Gonzalez; Nicholas K Sauter; R Paul Phizackerley; S Michael Soltis; Peter Kuhn
Journal:  J Synchrotron Radiat       Date:  2002-11-01       Impact factor: 2.616

2.  Refinement of macromolecular structures by the maximum-likelihood method.

Authors:  G N Murshudov; A A Vagin; E J Dodson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1997-05-01

3.  Systematic investigation of halogen bonding in protein-ligand interactions.

Authors:  Leo A Hardegger; Bernd Kuhn; Beat Spinnler; Lilli Anselm; Robert Ecabert; Martine Stihle; Bernard Gsell; Ralf Thoma; Joachim Diez; Jörg Benz; Jean-Marc Plancher; Guido Hartmann; David W Banner; Wolfgang Haap; François Diederich
Journal:  Angew Chem Int Ed Engl       Date:  2011-01-03       Impact factor: 15.336

4.  Small molecule regulation of protein conformation by binding in the Flap of HIV protease.

Authors:  Theresa Tiefenbrunn; Stefano Forli; Michael M Baksh; Max W Chang; Meaghan Happer; Ying-Chuan Lin; Alexander L Perryman; Jin-Kyu Rhee; Bruce E Torbett; Arthur J Olson; John H Elder; M G Finn; C David Stout
Journal:  ACS Chem Biol       Date:  2013-03-29       Impact factor: 5.100

5.  AutoDrug: fully automated macromolecular crystallography workflows for fragment-based drug discovery.

Authors:  Yingssu Tsai; Scott E McPhillips; Ana González; Timothy M McPhillips; Daniel Zinn; Aina E Cohen; Michael D Feese; David Bushnell; Theresa Tiefenbrunn; C David Stout; Bertram Ludaescher; Britt Hedman; Keith O Hodgson; S Michael Soltis
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-04-11

6.  Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.

Authors:  T Lee; G S Laco; B E Torbett; H S Fox; D L Lerner; J H Elder; C H Wong
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

Review 7.  Fragment screening and HIV therapeutics.

Authors:  Joseph D Bauman; Disha Patel; Eddy Arnold
Journal:  Top Curr Chem       Date:  2012

8.  Integration, scaling, space-group assignment and post-refinement.

Authors:  Wolfgang Kabsch
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

9.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

10.  Halogen-enriched fragment libraries as leads for drug rescue of mutant p53.

Authors:  Rainer Wilcken; Xiangrui Liu; Markus O Zimmermann; Trevor J Rutherford; Alan R Fersht; Andreas C Joerger; Frank M Boeckler
Journal:  J Am Chem Soc       Date:  2012-04-05       Impact factor: 15.419

View more
  11 in total

1.  A Novel Bromine-Containing Paroxetine Analogue Provides Mechanistic Clues for Binding Ambiguity at the Central Primary Binding Site of the Serotonin Transporter.

Authors:  Rachel D Slack; Ara M Abramyan; Helen Tang; Sitaram Meena; Bruce A Davis; Alessandro Bonifazi; JoLynn B Giancola; Jeffrey R Deschamps; Sett Naing; Hideaki Yano; Satinder K Singh; Amy Hauck Newman; Lei Shi
Journal:  ACS Chem Neurosci       Date:  2019-08-22       Impact factor: 4.418

2.  Structures of endothiapepsin-fragment complexes from crystallographic fragment screening using a novel, diverse and affordable 96-compound fragment library.

Authors:  Franziska U Huschmann; Janina Linnik; Karine Sparta; Monika Ühlein; Xiaojie Wang; Alexander Metz; Johannes Schiebel; Andreas Heine; Gerhard Klebe; Manfred S Weiss; Uwe Mueller
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2016-04-22       Impact factor: 1.056

Review 3.  Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery.

Authors:  Disha Patel; Joseph D Bauman; Eddy Arnold
Journal:  Prog Biophys Mol Biol       Date:  2014-08-10       Impact factor: 3.667

4.  A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Rui Zhao; Ravikiran S Yedidi; Debananda Das; Haydar Bulut; Nicole S Delino; Venkata Reddy Sheri; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

5.  Virtual screening with AutoDock Vina and the common pharmacophore engine of a low diversity library of fragments and hits against the three allosteric sites of HIV integrase: participation in the SAMPL4 protein-ligand binding challenge.

Authors:  Alexander L Perryman; Daniel N Santiago; Stefano Forli; Diogo Santos Martins; Arthur J Olson
Journal:  J Comput Aided Mol Des       Date:  2014-02-04       Impact factor: 3.686

Review 6.  Contemporary Use of Anomalous Diffraction in Biomolecular Structure Analysis.

Authors:  Qun Liu; Wayne A Hendrickson
Journal:  Methods Mol Biol       Date:  2017

7.  Fragment-Based Discovery of Novel Allosteric MEK1 Binders.

Authors:  Paolo Di Fruscia; Fredrik Edfeldt; Igor Shamovsky; Gavin W Collie; Anna Aagaard; Louise Barlind; Ulf Börjesson; Eva L Hansson; Richard J Lewis; Magnus K Nilsson; Linda Öster; Josefine Pemberton; Lena Ripa; R Ian Storer; Helena Käck
Journal:  ACS Med Chem Lett       Date:  2021-01-27       Impact factor: 4.345

8.  Distinguishing binders from false positives by free energy calculations: fragment screening against the flap site of HIV protease.

Authors:  Nanjie Deng; Stefano Forli; Peng He; Alex Perryman; Lauren Wickstrom; R S K Vijayan; Theresa Tiefenbrunn; David Stout; Emilio Gallicchio; Arthur J Olson; Ronald M Levy
Journal:  J Phys Chem B       Date:  2014-09-17       Impact factor: 2.991

9.  Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection.

Authors:  Katherine Sullivan; Kimberly Cramer-Morales; Daniel L McElroy; David A Ostrov; Kimberly Haas; Wayne Childers; Robert Hromas; Tomasz Skorski
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

10.  Elasticity-Associated Functionality and Inhibition of the HIV Protease.

Authors:  Dean Sherry; Roland Worth; Yasien Sayed
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.